Skip to main content
Premium Trial:

Request an Annual Quote

Pharmacopeia and Eos Call of Merger

NEW YORK, Jan. 18 - Call off the florists.


Pharmacopeia and Eos Biotechnology said late on Thursday that their boards have mutually agreed to kill the planned merger they announced last August.

"We remain optimistic about the future prospects of the science, technology and people at Pharmacopeia," said Joseph Mollica, chairman, president and CEO of Pharmacopeia.

"We believe there are many ways in which we can prosper by adding to and leveraging our existing biology and chemistry capabilities. We will continue to pursue the many alternatives available to us," said Mollica.

David Martin, president and CEO of Eos, added: "Eos has the people, technology, partners and vision to build a leading therapeutic development company. We will continue to move forward aggressively with our plans for other therapeutic candidates and look to partner when appropriate."

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.